Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

INTRODUCTION: Efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist being developed to improve glycemic control in type 2 diabetes (T2D). In the BALANCE 205 study (NCT02075281), efpeglenatide significantly reduced body weight versus placebo in patients with obesity, or overweight w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E, Jacob, Stephan, Baek, Seungjae, Trautmann, Michael E, Hompesch, Marcus, Han, OakPil, Stewart, John, Sorli, Christopher H, Shaunik, Alka, Yoon, Kun-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768911/
https://www.ncbi.nlm.nih.gov/pubmed/35042751
http://dx.doi.org/10.1136/bmjdrc-2021-002207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768911/
https://www.ncbi.nlm.nih.gov/pubmed/35042751
http://dx.doi.org/10.1136/bmjdrc-2021-002207

Ejemplares similares